The draft guidance make the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.

Essential Tools for Managing Hormone Receptor-Positive Breast Cancer Presented by Learn Look Locate and Walgreens “We know ...

Feb. 7, 2025 — A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 ...

Hormone receptor (HR)-positive HER2-negative advanced breast cancer is incurable and the aim of treatment is to delay it getting worse and extend how long people live. If the cancer has alterations in ...

Now, researchers have designed and synthesized new compounds that target the two enzymes. The new potential therapy is called a dual aromatase-steroid sulfatase inhibitor (DASI). Some of these new ...

“We have made broad commitments to cell therapy, and that's clear from EsoBiotec, but other things also,” Sapra said. “We have gone from autologous to building the allogeneic [and] now ...

Dr Paul Foster, co-author of the study The new potential therapy is called a dual aromatase-steroid sulfatase inhibitor (DASI). Some of these new compounds were found to effectively block both enzymes ...

an aromatase inhibitor in combination with a CDK4/6 as a front-line therapy for patients ER-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...